1
|
Jin H, Lu W, Zhang Y, Wu Y, Ding J, Orion IRCV, Liu C. Functionalized Periodic Mesoporous Silica Nanoparticles for Inhibiting the Progression of Atherosclerosis by Targeting Low-Density Lipoprotein Cholesterol. Pharmaceutics 2024; 16:74. [PMID: 38258085 PMCID: PMC10821319 DOI: 10.3390/pharmaceutics16010074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Revised: 12/27/2023] [Accepted: 12/30/2023] [Indexed: 01/24/2024] Open
Abstract
Atherosclerotic disease is a substantial global burden, and existing treatments, such as statins, are recommended to lower low-density lipoprotein cholesterol (LDL-C) levels and inhibit the progression of atherosclerosis. However, side effects, including gastrointestinal unease, potential harm to the liver, and discomfort in the muscles, might be observed. In this study, we propose a novel method using periodic mesoporous silica nanoparticles (PMS) to create heparin-modified PMS (PMS-HP) with excellent biocompatibility, enabling selective removal of LDL-C from the blood. In vitro, through the introduction of PMS-HP into the plasma of mice, we observed that, compared to PMS alone, PMS-HP could selectively adsorb LDL-C while avoiding interference with valuable components such as plasma proteins and high-density lipoprotein cholesterol (HDL-C). Notably, further investigations revealed that the adsorption of LDL-C by PMS-HP could be well-fitted to quasi-first-order (R2 = 0.993) and quasi-second-order adsorption models (R2 = 0.998). Likewise, in vivo, intravenous injection of PMS-HP enabled targeted LDL-C adsorption (6.5 ± 0.73 vs. 8.6 ± 0.76 mM, p < 0.001) without affecting other plasma constituents, contributing to reducing intravascular plaque formation (3.66% ± 1.06% vs. 1.87% ± 0.79%, p < 0.05) on the aortic wall and inhibiting vascular remodeling (27.2% ± 6.55% vs. 38.3% ± 1.99%, p < 0.05). Compared to existing lipid adsorption techniques, PMS-HP exhibited superior biocompatibility and recyclability, rendering it valuable for both in vivo and in vitro applications.
Collapse
Affiliation(s)
- Hao Jin
- Department of Cardiology, Zhongda Hospital Affiliated with Southeast University, Nanjing 210009, China; (H.J.); (Y.Z.); (Y.W.); (I.R.C.V.O.)
| | - Wenbin Lu
- Department of Cardiology, Zhongda Hospital Affiliated with Southeast University, Nanjing 210009, China; (H.J.); (Y.Z.); (Y.W.); (I.R.C.V.O.)
| | - Yahao Zhang
- Department of Cardiology, Zhongda Hospital Affiliated with Southeast University, Nanjing 210009, China; (H.J.); (Y.Z.); (Y.W.); (I.R.C.V.O.)
| | - Yong Wu
- Department of Cardiology, Zhongda Hospital Affiliated with Southeast University, Nanjing 210009, China; (H.J.); (Y.Z.); (Y.W.); (I.R.C.V.O.)
| | - Jiandong Ding
- Department of Cardiology, Zhongda Hospital Affiliated with Southeast University, Nanjing 210009, China; (H.J.); (Y.Z.); (Y.W.); (I.R.C.V.O.)
| | - I. R. Chiara Villamil Orion
- Department of Cardiology, Zhongda Hospital Affiliated with Southeast University, Nanjing 210009, China; (H.J.); (Y.Z.); (Y.W.); (I.R.C.V.O.)
| | - Cihui Liu
- Department of Biomedical Sciences, Nanjing Normal University, Nanjing 210023, China;
| |
Collapse
|
2
|
Kirla H, Henry DJ, Jansen S, Thompson PL, Hamzah J. Use of Silica Nanoparticles for Drug Delivery in Cardiovascular Disease. Clin Ther 2023; 45:1060-1068. [PMID: 37783646 DOI: 10.1016/j.clinthera.2023.08.017] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Revised: 08/22/2023] [Accepted: 08/24/2023] [Indexed: 10/04/2023]
Abstract
PURPOSE Cardiovascular disease (CVD) is the leading cause of death worldwide. The current CVD therapeutic drugs require long-term treatment with high doses, which increases the risk of adverse effects while offering only marginal treatment efficacy. Silica nanoparticles (SNPs) have been proven to be an efficient drug delivery vehicle for numerous diseases, including CVD. This article reviews recent progress and advancement in targeted delivery for drugs and diagnostic and theranostic agents using silica nanoparticles to achieve therapeutic efficacy and improved detection of CVD in clinical and preclinical settings. METHODS A search of PubMed, Scopus, and Google Scholar databases from 1990 to 2023 was conducted. Current clinical trials on silica nanoparticles were identified through ClinicalTrials.gov. Search terms include silica nanoparticles, cardiovascular diseases, drug delivery, and therapy. FINDINGS Silica nanoparticles exhibit biocompatibility in biological systems, and their shape, size, surface area, and surface functionalization can be customized for the safe transport and protection of drugs in blood circulation. These properties also enable effective drug uptake in specific tissues and controlled drug release after systemic, localized, or oral delivery. A range of silica nanoparticles have been used as nanocarrier for drug delivery to treat conditions such as atherosclerosis, hypertension, ischemia, thrombosis, and myocardial infarction. IMPLICATIONS The use of silica nanoparticles for drug delivery and their ongoing development has emerged as a promising strategy to improve the effectiveness of drugs, imaging agents, and theranostics with the potential to revolutionize the treatment of CVD.
Collapse
Affiliation(s)
- Haritha Kirla
- Targeted Drug Delivery, Imaging & Therapy Laboratory, Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands, Western Australia, Australia; Chemistry and Physics, College of Science, Health, Engineering and Education, Murdoch University, Western Australia, Australia.
| | - David J Henry
- Chemistry and Physics, College of Science, Health, Engineering and Education, Murdoch University, Western Australia, Australia
| | - Shirley Jansen
- Targeted Drug Delivery, Imaging & Therapy Laboratory, Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands, Western Australia, Australia; Curtin Health Innovation Research Institute and Curtin Medical School, Curtin University, Perth, Western Australia, Australia; Heart & Vascular Research Institute, Harry Perkins Institute of Medical Research, Nedlands, Western Australia, Australia; Department of Vascular and Endovascular Surgery, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia
| | - Peter L Thompson
- Heart & Vascular Research Institute, Harry Perkins Institute of Medical Research, Nedlands, Western Australia, Australia
| | - Juliana Hamzah
- Targeted Drug Delivery, Imaging & Therapy Laboratory, Harry Perkins Institute of Medical Research, QEII Medical Centre, Nedlands, Western Australia, Australia; Curtin Health Innovation Research Institute and Curtin Medical School, Curtin University, Perth, Western Australia, Australia; Heart & Vascular Research Institute, Harry Perkins Institute of Medical Research, Nedlands, Western Australia, Australia.
| |
Collapse
|
3
|
Lu W, Jin H, Ding J, Zhang Y, Wu Y. New application of a periodic mesoporous nanocrystal silicon-silica composite for hyperlipidemia. Nanoscale Adv 2023; 5:4286-4297. [PMID: 37560424 PMCID: PMC10408577 DOI: 10.1039/d3na00467h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Accepted: 07/08/2023] [Indexed: 08/11/2023]
Abstract
The integration of the properties of silicon nano crystallinity with silica mesoporosity provides a wealth of new opportunities for emerging biomedicine. Cholesterol (CHO) and triglyceride (TG) levels have always been a challenge for cardiologists in the treatment of patients with chronic coronary artery disease (CAD). For patients with hyperlipidemia, statins and other lipid-lowering drugs are currently recommended. It should be noted, however, that significant side effects have been reported in the treatments, including liver damage, muscle pain, etc. We here found that our previously produced periodic mesoporous nanocrystalline silicon-silica, meso-ncSi/SiO2 (PMS), a nanocomposite material, has the properties of lowering CHO and TG, and is associated with better safety and biocompatibility compared to existing lipid-lowering drugs. After being incubated with PMS for 2 hours, CHO and TG levels in blood were significantly lower than before. In addition, CHO and TG adsorbed on with PMS could also be extracted and released, contributing to the recovery and recycling of PMS.
Collapse
Affiliation(s)
- Wenbin Lu
- Department of Cardiology, Zhongda Hospital, Southeast University 87#, Dingjiaqiao Road Nanjing 210009 China
| | - Hao Jin
- Department of Cardiology, Zhongda Hospital, Southeast University 87#, Dingjiaqiao Road Nanjing 210009 China
| | - Jiandong Ding
- Department of Cardiology, Zhongda Hospital, Southeast University 87#, Dingjiaqiao Road Nanjing 210009 China
| | - Yahao Zhang
- Department of Cardiology, Zhongda Hospital, Southeast University 87#, Dingjiaqiao Road Nanjing 210009 China
| | - Yong Wu
- Department of Cardiology, Zhongda Hospital, Southeast University 87#, Dingjiaqiao Road Nanjing 210009 China
| |
Collapse
|
4
|
Iqbal M, Robert-Nicoud G, Ciurans-Oset M, Akhtar F, Hedin N, Bengtsson T. Mesoporous Silica Particles Retain Their Structure and Function while Passing through the Gastrointestinal Tracts of Mice and Humans. ACS Appl Mater Interfaces 2023; 15:9542-9553. [PMID: 36731867 PMCID: PMC9951217 DOI: 10.1021/acsami.2c16710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Accepted: 01/24/2023] [Indexed: 06/18/2023]
Abstract
Mesoporous silica particles (MSPs) can be used as food additives, clinically for therapeutic applications, or as oral delivery vehicles. It has also been discussed to be used for a number of novel applications including treatment for diabetes and obesity. However, a major question for their possible usage has been if these particles persist structurally and retain their effect when passing through the gastrointestinal tract (GIT). A substantial breaking down of the particles could reduce function and be clinically problematic for safety issues. Hence, we investigated the biostability of MSPs of the SBA-15 kind prepared at large scales (100 and 1000 L). The MSPs were orally administered in a murine model and clinically in humans. A joint extraction and calcination method was developed to recover the MSPs from fecal mass, and the MSPs were characterized physically, structurally, morphologically, and functionally before and after GIT passage. Analyses with N2 adsorption, X-ray diffraction, electron microscopy, and as a proxy for general function, adsorption of the enzyme α-amylase, were conducted. The adsorption capacity of α-amylase on extracted MSPs was not reduced as compared to the pristine and control MSPs, and adsorption of up to 17% (w/w) was measured. It was demonstrated that the particles did not break down to any substantial degree and retained their function after passing through the GITs of the murine model and in humans. The fact the particles were not absorbed into the body was ascribed to that they were micron-sized and ingested as agglomerates and too big to pass the intestinal barrier. The results strongly suggest that orally ingested MSPs can be used for a number of clinical applications.
Collapse
Affiliation(s)
- Muhammad
Naeem Iqbal
- Department
of Materials and Environmental Chemistry, Stockholm University, StockholmSE-106 91, Sweden
- Sigrid
Therapeutics AB, Stockholm, Stockholm113 29, Sweden
| | - Ghislaine Robert-Nicoud
- Department
of Materials and Environmental Chemistry, Stockholm University, StockholmSE-106 91, Sweden
- Sigrid
Therapeutics AB, Stockholm, Stockholm113 29, Sweden
| | - Marina Ciurans-Oset
- Division
of Materials Science, Department of Engineering Sciences and Mathematics, Luleå University of Technology, LuleåSE-971 87, Sweden
| | - Farid Akhtar
- Division
of Materials Science, Department of Engineering Sciences and Mathematics, Luleå University of Technology, LuleåSE-971 87, Sweden
| | - Niklas Hedin
- Department
of Materials and Environmental Chemistry, Stockholm University, StockholmSE-106 91, Sweden
| | - Tore Bengtsson
- Sigrid
Therapeutics AB, Stockholm, Stockholm113 29, Sweden
- Department
of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, StockholmSE-106 91, Sweden
| |
Collapse
|
5
|
Chen J, Hanrahan JP, McGrath J, Courtney MA, Prestidge CA, Joyce P. The Anti-Obesity Effect of Porous Silica Is Dependent on Pore Nanostructure, Particle Size, and Surface Chemistry in an In Vitro Digestion Model. Pharmaceutics 2022; 14:pharmaceutics14091813. [PMID: 36145561 PMCID: PMC9502391 DOI: 10.3390/pharmaceutics14091813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2022] [Revised: 08/24/2022] [Accepted: 08/26/2022] [Indexed: 11/16/2022] Open
Abstract
The potential for porous silica to serve as an effective anti-obesity agent has received growing attention in recent years. However, neither the exact pharmacological mechanism nor the fundamental physicochemical properties of porous silica that drive its weight-lowering effect are well understood. Subsequently, in this study, an advanced in vitro digestion model capable of monitoring lipid and carbohydrate digestion was employed to elucidate the effect of porous silica supplementation on digestive enzyme activities. A suite of porous silica samples with contrasting physicochemical properties was investigated, where it was established that the inhibitory action of porous silica on digestive enzyme functionality was strongly dependent on porous nanostructure, particle size and morphology, and surface chemistry. Insights derived from this study validate the capacity of porous silica to impede the digestive processes mediated by pancreatic lipase and α-amylase within the gastrointestinal tract, while the subtle interplay between porous nanostructure and enzyme inhibition indicates that the anti-obesity effect can be optimized through strategic particle design.
Collapse
Affiliation(s)
- JingYi Chen
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia
| | | | - Joe McGrath
- Glantreo Limited, ERI Building Lee Road, T23 XE10 Cork, Ireland
| | | | - Clive A. Prestidge
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia
| | - Paul Joyce
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide, SA 5000, Australia
- Correspondence:
| |
Collapse
|
6
|
Baek J, Robert-Nicoud G, Herrera Hidalgo C, Borg ML, Iqbal MN, Berlin R, Lindgren M, Waara E, Uddén A, Pietiläinen K, Bengtsson T. Engineered mesoporous silica reduces long-term blood glucose, HbA1c, and improves metabolic parameters in prediabetics. Nanomedicine (Lond) 2021; 17:9-22. [PMID: 34854740 DOI: 10.2217/nnm-2021-0235] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
Aim: To investigate the effect of oral consumption of engineered mesoporous silica particles, SiPore15®, on long-term blood glucose levels and other metabolic parameters in individuals with prediabetes and newly diagnosed Type 2 diabetes. Method: An open-label, single-arm, multicenter trial was conducted in which SiPore15 was consumed three times daily for 12 weeks. Hemoglobin A1c (HbA1c, primary end point) and an array of metabolic parameters were measured at baseline and throughout the trial. Result: SiPore15 treatment significantly reduced HbA1c by a clinically meaningful degree and improved several disease-associated parameters with minimal side effects. Conclusion: The results from this study demonstrate the potential use of SiPore15 as a treatment for prediabetes that may also delay or prevent the onset of Type 2 diabetes.
Collapse
Affiliation(s)
- Jeanha Baek
- Sigrid Therapeutics AB, Norrtullsgatan 6, Stockholm, SE-113 29, Sweden
| | | | | | - Melissa L Borg
- Sigrid Therapeutics AB, Norrtullsgatan 6, Stockholm, SE-113 29, Sweden
| | - Muhammad N Iqbal
- Sigrid Therapeutics AB, Norrtullsgatan 6, Stockholm, SE-113 29, Sweden.,Department of Materials and Environmental Chemistry, Stockholm University, Stockholm, SE-106 91, Sweden
| | - Roger Berlin
- 1.618 Consulting LLC, Philadelphia, PA 19107, USA
| | - Maria Lindgren
- Sigrid Therapeutics AB, Norrtullsgatan 6, Stockholm, SE-113 29, Sweden
| | - Erik Waara
- Sigrid Therapeutics AB, Norrtullsgatan 6, Stockholm, SE-113 29, Sweden
| | - Anna Uddén
- Sigrid Therapeutics AB, Norrtullsgatan 6, Stockholm, SE-113 29, Sweden
| | - Kirsi Pietiläinen
- Obesity Research Unit, Research Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, 00014, Finland.,Obesity Center, Abdominal Center, Helsinki University Hospital and University of Helsinki, Helsinki, 00014, Finland
| | - Tore Bengtsson
- Department of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, SE-106 91, Sweden
| |
Collapse
|
7
|
Sun L, Sogo Y, Wang X, Ito A. Biosafety of mesoporous silica nanoparticles: a combined experimental and literature study. J Mater Sci Mater Med 2021; 32:102. [PMID: 34406531 PMCID: PMC8373747 DOI: 10.1007/s10856-021-06582-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/23/2021] [Accepted: 06/28/2021] [Indexed: 05/03/2023]
Abstract
Mesoporous silica (MS) particles have been explored for various healthcare applications, but universal data about their safety and/or toxicity are yet to be well-established for clinical purposes. Information about general toxicity of hollow MS (HMS) particles and about immunotoxicity of MS particles are significantly lacked. Therefore, acute toxicity and immunotoxicity of HMS particles were experimentally evaluated. A systematic and objective literature study was parallelly performed to analyze the published in vivo toxicity of MS particles. Lethal acute toxicity of MS particles is likely to arise from their physical action after intravenous and intraperitoneal administrations, and only rarely observed after subcutaneous administration. No clear relationship was identified between physicochemical properties of MS particles and lethality as well as maximum tolerated dose with some exceptions. At sub-lethal doses, MS particles tend to accumulate mainly in lung, liver, and spleen. The HMS particles showed lower inflammation-inducing ability than polyinosinic-polycytidylic acid and almost the same allergy-inducing ability as Alum. Finally, the universal lowest observed adverse effect levels were determined as 0.45, 0.81, and 4.1 mg/kg (human equivalent dose) for intravenous, intraperitoneal, and subcutaneous administration of MS particles, respectively. These results could be helpful for determining an appropriate MS particle dose in clinical study.
Collapse
Affiliation(s)
- Lue Sun
- Health and Medical Research Institute, Department of Life Science and Biotechnology, National Institute of Advanced Industrial Science and Technology (AIST), Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8566, Japan
| | - Yu Sogo
- Health and Medical Research Institute, Department of Life Science and Biotechnology, National Institute of Advanced Industrial Science and Technology (AIST), Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8566, Japan.
| | - Xiupeng Wang
- Health and Medical Research Institute, Department of Life Science and Biotechnology, National Institute of Advanced Industrial Science and Technology (AIST), Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8566, Japan
| | - Atsuo Ito
- Health and Medical Research Institute, Department of Life Science and Biotechnology, National Institute of Advanced Industrial Science and Technology (AIST), Central 6, 1-1-1 Higashi, Tsukuba, Ibaraki, 305-8566, Japan
| |
Collapse
|
8
|
Mares-García AS, Ortiz Magdaleno M, Gordillo-Moscoso A, Cárdenas-Galindo MG, Ávila Hernández IN, Escobar-García DM, Márquez-Lucero A, Pozos-Guillén A. Morphological and biological properties of silica nanoparticles for CRTC3-siRNA delivery and downregulation of the RGS2 expression in preadipocytes. J Biomater Appl 2021; 36:626-637. [PMID: 33947275 DOI: 10.1177/08853282211014723] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The aim of this study was to characterize the morphological properties of amorphous silica nanoparticles (SiO2 NPs), their cytotoxicity and intracellular location within Human Osteoblasts (HOB). Additionally, SiO2 NPs were explored for their effectivity as carriers of CRTC3-siRNA on Human Preadipocytes (HPAd), and thus downregulate RGS2 gene expression. SiO2 NPs were synthesized using the method of Stöber at 45 °C, 56 °C, and 62 °C. These were characterized via TEM with EDS, Zeta Potential and FT-IR. Cytotoxicity was evaluated by XTT at three concentrations 50, 100 and 500 µg/mL; SiO2 NPs intracellular localization was observed through Confocal Laser Scanning Microscope. Delivering siRNA effectivity was measured by RT-qPCR. Morphology of SiO2 NPs was spherical with a range size from 64 to 119 nm; their surface charge was negative. Confocal images demonstrated that SiO2 NPs were located within cellular cytoplasm. At a SiO2 NPs concentration of 500 µg/mL HOB viability decreased, while at 50 µg/mL and 100 µg/mL cell viability was not affected regardless SiO2 NPs size. SiO2 NPs-CRTC3-siRNA are effective to down-regulate RGS2 gene expression in HPAd without cytotoxic effects. The developed SiO2 NPs-CRTC3-siRNA are a promising tool as a delivery vehicle to control obesity.
Collapse
Affiliation(s)
- América Susana Mares-García
- Doctorado Institucional en Ingeniería y Ciencia de Materiales, , Universidad Autonoma de San Luis Potosi, San Luis, SLP, Mexico
| | - Marine Ortiz Magdaleno
- Doctorado Institucional en Ingeniería y Ciencia de Materiales, , Universidad Autonoma de San Luis Potosi, San Luis, SLP, Mexico
| | - Antonio Gordillo-Moscoso
- Doctorado Institucional en Ingeniería y Ciencia de Materiales, , Universidad Autonoma de San Luis Potosi, San Luis, SLP, Mexico
| | | | - Ilse Nayeli Ávila Hernández
- Doctorado Institucional en Ingeniería y Ciencia de Materiales, , Universidad Autonoma de San Luis Potosi, San Luis, SLP, Mexico
| | - Diana María Escobar-García
- Doctorado Institucional en Ingeniería y Ciencia de Materiales, , Universidad Autonoma de San Luis Potosi, San Luis, SLP, Mexico
| | - Alfredo Márquez-Lucero
- Doctorado Institucional en Ingeniería y Ciencia de Materiales, , Universidad Autonoma de San Luis Potosi, San Luis, SLP, Mexico
| | - Amaury Pozos-Guillén
- Doctorado Institucional en Ingeniería y Ciencia de Materiales, , Universidad Autonoma de San Luis Potosi, San Luis, SLP, Mexico
| |
Collapse
|
9
|
Affiliation(s)
- Alice Bough
- Future Science Group, Unitec House, 2 Albert Place, London, N3 1QB, UK
| |
Collapse
|
10
|
Joyce P, Dening TJ, Meola TR, Wignall A, Ulmefors H, Kovalainen M, Prestidge CA. Contrasting Anti-obesity Effects of Smectite Clays and Mesoporous Silica in Sprague-Dawley Rats. ACS Appl Bio Mater 2020; 3:7779-7788. [PMID: 35019518 DOI: 10.1021/acsabm.0c00969] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Porous colloids have been shown to exert unique bioactivities for mediating lipid (fat) metabolism and thereby offer significant potential as anti-obesity therapies. In this study, we compare the capacity for two classes of colloids, that is, smectite clays (Laponite XLG, LAP; montmorillonite, MMT) and mesoporous silica (SBA-15 ordered silica; MPS), to impede intestinal lipid hydrolysis and provoke lipid and carbohydrate excretion through adsorption within their particle matrices. A two-stage in vitro gastrointestinal lipolysis model revealed the capacity for both smectite clays and MPS to inhibit the rate and extent of lipase-mediated digestion under simulated fed state conditions. Each system adsorbed more than its own weight of organic media (i.e., lipid and carbohydrates) after 60 min lipolysis, with MMT adsorbing >10% of all available organics through the indiscriminate adsorption of fatty acids and glycerides. When co-administered with a high-fat diet (HFD) to Sprague-Dawley rats, treatment with MMT and MPS significantly reduced normalized rodent weight gain compared to a negative control, validating their potential to restrict energy intake and serve as anti-obesity therapies. However, in vitro-in vivo correlations revealed poor associations between in vitro digestion parameters and normalized weight gain, indicating that additional/alternate anti-obesity mechanisms may exist in vivo, while also highlighting the need for improved in vitro assessment methodologies. Despite this, the current findings emphasize the potential for porous colloids to restrict weight gain and promote anti-obesity effects to subjects exposed to a HFD and should therefore drive the development of next-generation food-grade biomaterials for the treatment and prevention of obesity.
Collapse
Affiliation(s)
- Paul Joyce
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, South Australia, Australia
| | - Tahnee J Dening
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, South Australia, Australia
| | - Tahlia R Meola
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, South Australia, Australia
| | - Anthony Wignall
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, South Australia, Australia
| | - Hanna Ulmefors
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, South Australia, Australia
| | - Miia Kovalainen
- Research Unit of Biomedicine and Biocenter of Oulu, Faculty of Medicine, University of Oulu, P.O. Box 5000, Oulu FI-90014, Finland
| | - Clive A Prestidge
- UniSA Clinical & Health Sciences, University of South Australia, Adelaide 5000, South Australia, Australia.,ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, University of South Australia, Adelaide 5000, South Australia, Australia
| |
Collapse
|
11
|
Waara ER, Iqbal MN, Robert‐Nicoud G, Benziane B, Vallhov H, Wasik AM, Lindgren M, Hagman E, Rinde M, Kupferschmidt N, Berlin R, Johnston EV, Danielsson P, Bengtsson T. Entrapping Digestive Enzymes with Engineered Mesoporous Silica Particles Reduces Metabolic Risk Factors in Humans. Adv Healthc Mater 2020; 9:e2000057. [PMID: 32352221 DOI: 10.1002/adhm.202000057] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2020] [Revised: 04/08/2020] [Indexed: 12/29/2022]
Abstract
Engineered mesoporous silica particles (MSP) are thermally and chemically stable porous materials composed of pure silica and have attracted attention for their potential biomedical applications. Oral intake of engineered MSP is shown to reduce body weight and adipose tissue in mice. Here, clinical data from a first-in-humans study in ten healthy individuals with obesity are reported, demonstrating a reduction in glycated hemoglobin (HbA1c) and low-density lipoprotein cholesterol, which are well-established metabolic and cardiovascular risk factors. In vitro investigations demonstrate sequestration of pancreatic α-amylase and lipase in an MSP pore-size dependent manner. Subsequent ex vivo experiments in conditions mimicking intestinal conditions and in vivo experiments in mice show a decrease in enzyme activity upon exposure to the engineered MSP, presumably by the same mechanism. Therefore, it is suggested that tailored MSP act by lowering the digestive enzyme availability in the small intestine, resulting in decreased digestion of macronutrient and leading to reduced caloric uptake. This novel MSP based mechanism-of-action, combined with its excellent safety in man, makes it a promising future agent for prevention and treatment of metabolic diseases.
Collapse
Affiliation(s)
- Erik R. Waara
- Stockholm University Stockholm 106 91 Sweden
- Sigrid Therapeutics AB Stockholm 171 65 Sweden
| | - Muhammad N. Iqbal
- Stockholm University Stockholm 106 91 Sweden
- Sigrid Therapeutics AB Stockholm 171 65 Sweden
| | | | | | | | - Agata M. Wasik
- Sigrid Therapeutics AB Stockholm 171 65 Sweden
- Karolinska Institutet Stockholm 171 77 Sweden
| | | | | | - Mia Rinde
- Stockholm University Stockholm 106 91 Sweden
| | | | | | | | | | - Tore Bengtsson
- Sigrid Therapeutics AB Stockholm 171 65 Sweden
- Department of Molecular BiosciencesThe Wenner‐Gren InstituteStockholm University Stockholm 106 91 Sweden
| |
Collapse
|
12
|
|